Results 331 to 340 of about 13,097,347 (378)
Amphotericin B Encapsulation in Polymeric Nanoparticles: Toxicity Insights via Cells and Zebrafish Embryo Testing. [PDF]
PharmaceuticsMaciel-Magalhães M +10 more
europepmc +1 more source
Efficacy and Safety of Amphotericin B Colloidal Dispersion via Nebulized Inhalation Combined with Intravenous Therapy for Invasive Pulmonary Fungal Disease: A Single-Center, Retrospective Cohort Study. [PDF]
Infect Drug ResistLi Z, Li F, Chen T, Yang R.
europepmc +1 more source
Voriconazole is inferior to amphotericin B deoxycholate as the initial induction therapy for HIV-associated Talaromyces marneffei fungemia: A multicenter retrospective study. [PDF]
PLoS Negl Trop DisYe S +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Applied Microbiology and Biotechnology, 2005
Invasive fungal infections are a major cause of morbidity and mortality in immunodeficient individuals (such as AIDS patients) and in transplant recipients or tumor patients undergoing immunosuppressive chemotherapy. Amphotericin B is one of the oldest, yet most efficient antimycotic agents. However, its usefulness is limited due to dose-dependent side-
Lemke, A. +2 more
openaire +3 more sources
Invasive fungal infections are a major cause of morbidity and mortality in immunodeficient individuals (such as AIDS patients) and in transplant recipients or tumor patients undergoing immunosuppressive chemotherapy. Amphotericin B is one of the oldest, yet most efficient antimycotic agents. However, its usefulness is limited due to dose-dependent side-
Lemke, A. +2 more
openaire +3 more sources
Amphotericin B and Coccidioidomycosis
Annals of the New York Academy of Sciences, 2007Abstract: Prior to the 1950s no effective therapy for coccidioidomycosis existed. The advent of amphotericin B ushered in the therapeutic era for coccidioidomycosis. Until this time amphotericin B and its lipid congeners have been regarded as the “gold standard” of therapy for severe pulmonary and disseminated coccidioidomycosis.
Royce H. Johnson, Hans E. Einstein
openaire +3 more sources
Pediatrics In Review, 1995
There are many circumstances in which pediatricians today may be involved in the care of patients at risk for systemic fungal infection. Among those at risk are children receiving chemotherapy for neoplastic disease, children infected with human immunodeficiency virus (HIV), and children undergoing immunosuppressive therapy for chronic illnesses or ...
openaire +2 more sources
There are many circumstances in which pediatricians today may be involved in the care of patients at risk for systemic fungal infection. Among those at risk are children receiving chemotherapy for neoplastic disease, children infected with human immunodeficiency virus (HIV), and children undergoing immunosuppressive therapy for chronic illnesses or ...
openaire +2 more sources
Amphotericin B and Maduromycosis
Archives of Pediatrics & Adolescent Medicine, 1978Sir .—Let me react to the clinical memorandum on the treatment of Maduromycosis with amphotericin B by Hayden et al in theJournal(131:927, 1977). We would point out that our case, to which they refer in their third reference, also had "apparent remission," but recurred thereafter.
openaire +3 more sources
Drug Safety, 1990
The frequency of fungal infections is increasing. Amphotericin B remains the anti-fungal drug of choice for most systemic infections, but a limiting factor for its use is the development of nephrotoxicity. Amphotericin B-induced nephrotoxicity is manifested as azotaemia, renal tubular acidosis, impaired renal concentrating ability and electrolyte ...
Ramzi Sabra, Robert A. Branch
openaire +3 more sources
The frequency of fungal infections is increasing. Amphotericin B remains the anti-fungal drug of choice for most systemic infections, but a limiting factor for its use is the development of nephrotoxicity. Amphotericin B-induced nephrotoxicity is manifested as azotaemia, renal tubular acidosis, impaired renal concentrating ability and electrolyte ...
Ramzi Sabra, Robert A. Branch
openaire +3 more sources
2003
Abstract Amphotericin B has been the cornerstone of antifungal therapy for almost 50 years. Discovered in the late 1950s, it was approved for human use as an antimycotic in 1960. Initial formulations of amphotericin B were plagued with impurities.
Stanley W Chapman +2 more
openaire +1 more source
Abstract Amphotericin B has been the cornerstone of antifungal therapy for almost 50 years. Discovered in the late 1950s, it was approved for human use as an antimycotic in 1960. Initial formulations of amphotericin B were plagued with impurities.
Stanley W Chapman +2 more
openaire +1 more source